December 21, 2007

Jerini Receives NDA Filing Acceptance and Priority Review from the FDA for Icatibant in the Treatment of HAE

September 4, 2007

Jerini Regains Commercialization Rights to Icatibant for the Treatment of Hereditary Angioedema in North America

August 16, 2007

Jerini Receives EMEA Filing Acceptance of its Marketing Application for Icatibant in the Treatment of Hereditary Angioedema

February 27, 2007

Jerini Plans to Submit US New Drug Application in Third Quarter 2007 for Icatibant in Hereditary Angioedema